AA
NUVB icon

AlphaCentric Advisors’s Nuvation Bio NUVB Stock Holding History

AlphaCentric Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-135,000
Closed -$309K – 263
2024
Q3 		$309K Hold
135,000
– – 0.23% 108
2024
Q2 		$394K Hold
135,000
– – 0.29% 87
2024
Q1 		$491K Sell
135,000
-315,000
-70% -$605K 0.3% 87
2023
Q4 		$680K Buy
450,000
+40,000
+10% +$51.5K 0.46% 65
2023
Q3 		$549K Buy
410,000
+65,000
+19% +$108K 0.31% 86
2023
Q2 		$621K Hold
345,000
– – 0.34% 89
2023
Q1 		$573K Buy
345,000
+20,000
+6% +$40.5K 0.4% 80
2022
Q4 		$624K Buy
325,000
+110,000
+51% +$223K 0.62% 61
2022
Q3 		$482K Buy
+215,000
New +$614K 0.49% 56

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

AlphaCentric Advisors's NUVB Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Nuvation Bio (NUVB) in Q4 2024, closing a stake of 135,000 shares — an estimated $309K sold.

AlphaCentric Advisors first reported a position in NUVB in Q3 2022 and held it in 9 quarters. The position peaked at $680K in Q4 2023. 160 funds tracked by Wall St. Rank hold NUVB as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Nuvation Bio position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 135,000 Nuvation Bio shares in Q4 2024, an estimated $309K.
  • AlphaCentric Advisors first reported a position in Nuvation Bio in Q3 2022 and held it in 9 quarters.
  • AlphaCentric Advisors's Nuvation Bio position peaked at $680K in Q4 2023.
  • 160 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.